tldrdaily.news logo

FDA Approves First Oral Microbiome Therapy for C. difficile Infections

1 min read
Source: FDA.gov
FDA Approves First Oral Microbiome Therapy for C. difficile Infections
Photo: FDA.gov
TL;DR Summary

The FDA has approved Vowst, the first orally administered fecal microbiota product, for the prevention of recurrence of Clostridioides difficile infection in individuals 18 years and older. CDI is a common healthcare-associated infection in the US and is associated with 15,000 to 30,000 deaths annually. Vowst contains live bacteria and is manufactured from human fecal matter that has been donated by qualified individuals. The dosing regimen is four capsules taken once a day, orally, for three consecutive days.

Topics:business#antibiotics#clostridioides-difficile#fda#health#microbiome#vowst
Share this article
  1. FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection  FDA.gov
  2. US FDA approves Seres Therapeutics' pill for deadly C. difficile infections  Reuters
  3. FDA approves first oral microbiome therapy Vowst. Will Nestlé be around to help Seres with the launch?  FiercePharma
  4. View Full Coverage on Google News

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

3 min

vs 4 min read

Condensed

87%

610 → 78 words

Want the full story? Read the original article

Read on FDA.gov